•
Dec 31, 2021

ResMed Q2 2022 Earnings Report

ResMed's second-quarter results reflected continued strong performance, resulting in double-digit top-line revenue growth and solid growth in software-as-a-service business.

Key Takeaways

ResMed Inc. announced results for the quarter ended December 31, 2021. Revenue increased by 12% to $894.9 million, and diluted earnings per share were $1.37.

Revenue increased by 12% to $894.9 million; up 13% on a constant currency basis.

Diluted earnings per share of $1.37; non-GAAP diluted earnings per share of $1.47.

Income from operations increased 12%; non-GAAP operating profit up 5%.

Gross margin of 56.4%; non-GAAP gross margin contracted 230 bps to 57.6%.

Total Revenue
$895M
Previous year: $800M
+11.9%
EPS
$1.47
Previous year: $1.41
+4.3%
Gross Profit
$504M
Previous year: $462M
+9.0%
Cash and Equivalents
$194M
Previous year: $256M
-24.0%
Free Cash Flow
$189M
Previous year: $135M
+40.4%
Total Assets
$4.73B
Previous year: $4.57B
+3.5%

ResMed

ResMed

ResMed Revenue by Segment

ResMed Revenue by Geographic Location

Forward Guidance

No specific forward guidance was provided in the press release.